NMS · Biotechnology

STTK (STTK) Stock

$6.78 -3.69% NMS: STTK Healthcare

Valuation

MetricValue
Price$6.78
Market Cap$324.78M
P/E Ratio-8.27
P/B Ratio3.38
P/S Ratio286.79
EPS (TTM)$-0.70
52-Week High$8.33
52-Week Low$0.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.76%
ROA-53.85%
ROCE-63.41%
Gross Margin-5200.00%
Operating Margin-5200.00%
Net Margin-49.87%
Debt/Equity0.02
Current Ratio11.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$30.0M$1.0M$2.0M$6.0M$1.0M
Operating Profit$-45.0M$-103.0M$-92.0M$-81.0M$-52.0M
Net Profit$-45.0M$-102.0M$-87.0M$-75.0M$-49.0M
EPS$-1.07$-2.41$-2.05$-1.49$-0.70
Op Margin-150.8%-15848.0%-5549.6%-1408.3%-5150.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$299.0M$205.0M$160.0M$91.0M$91.0M
Total Liabilities$27.0M$29.0M$15.0M$11.0M$9.0M
Cash$92.0M$47.0M$126.0M$57.0M$54.0M
Borrowings$0$5.0M$4.0M$3.0M$2.0M

Latest News

Netflix upgraded, Microsoft initiated: Wall Street's top analyst calls The Fly · Jul 20, 2026 Shattuck Labs Prices $75 Million Public Offering MT Newswires · Jun 10, 2026 Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering GlobeNewswire · Jun 10, 2026 Shattuck Labs Launches Public Offering of Common Stock MT Newswires · Jun 9, 2026 Shattuck Labs, Inc. Announces Proposed Public Offering GlobeNewswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-57.0M$-94.0M$-81.0M$-61.0M$-40.0M
Investing Cash Flow$-18.0M$38.0M$110.0M$-9.0M$-8.0M
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$-66.0M$-45.0M$78.0M$-68.0M$-3.0M
Free Cash Flow$-65.0M$-106.0M$-82.0M$-61.0M$-40.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-14.39%
Quick Ratio22.06
Interest Coverage—
Return 1Y764.63%
Return 3Y167.55%
Return 5Y-71.86%

Ownership

Insiders Held4.53%
Institutions Held60.05%
Institutions Float Held62.90%
Institutional HolderSharesReport Date
T. Rowe Price Investment Management, Inc.9,865,5582026-03-31
Orbimed Advisors LLC.6,306,1272026-03-31
Redmile Group, LLC5,539,7242026-03-31
Prosight Management, Lp5,004,4392026-03-31
Adage Capital Partners GP L.L.C.4,644,9572026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
IFRX $1.84 +6.98% -4.16 $132.91M 0.00%
IMA $5.69 +1.07% -1.49 $64.18M 0.00%

About STTK

STTK is led by CEO Taylor H. Schreiber, employs 44 people, headquartered in US, publicly traded since 2020.

STTK stock trades at $6.78 with a market capitalization of $324.78M. The stock is valued at a price-to-earnings (P/E) ratio of -8.27, price-to-book of 3.38, price-to-sales of 286.79. Over the past 52 weeks the stock has ranged between $0.71 and $8.33, and currently trades 18.6% below its 52-week high.

On profitability, STTK generates a return on equity (ROE) of -59.76%, return on capital employed of -63.41%, an operating margin of -5200.00%, a net profit margin of -49.87%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides